ERBB2 and breast cancer: This agrees with previous reports that stated HER2 protein over‐expression (IHC score 3+) is the key driver of HER2 oncogenic activity and is highly enriched with HER2 signalling pathway genes compared to borderline HER2‐positive BC with evidence of gene amplification [42, 52].